Nudge Strategies for DPYD Testing in Patients With Gastrointestinal Cancers Treated With Fluoropyrimidines
Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Aug 16, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
INTRODUCTION AND PURPOSE:
Fluoropyrimidines (FPs) are the cornerstone of treatment for several gastrointestinal (GI) malignancies. Approximately 5-7% of patients carry reduced function variants in DPYD, resulting in the inability to metabolize FPs, predisposing them to severe, life-threatening toxicities. These patients can be identified through DPYD pharmacogenetic (PGx) testing. However, DPYD testing has not been widely adopted in clinical care due to implementation barriers at the system- (e.g., access to testing, integration into clinical workflows), clinician- (e.g., interpretation of...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Fluent in English
- • Currently involved in the practice or policy of GI oncology/DPYD testing/FP use/Healthcare Development OR
- • Prescribed a FP for GI cancer diagnosis in the past six months AND Currently licensed to provide health care in Pennsylvania or New Jersey OR
- • Previous diagnosis of GI malignancy or family member who had GI malignancy
- Exclusion Criteria:
- • Less than 18 years old
About Abramson Cancer Center At Penn Medicine
The Abramson Cancer Center at Penn Medicine is a leading academic institution dedicated to advancing cancer research, treatment, and prevention. As part of the University of Pennsylvania, the center integrates cutting-edge scientific discovery with comprehensive clinical care, offering patients access to innovative therapies and clinical trials. Renowned for its multidisciplinary approach, the Abramson Cancer Center collaborates with experts across various specialties to deliver personalized treatment plans while fostering a supportive environment for patients and their families. Committed to improving outcomes and quality of life for cancer patients, the center is at the forefront of groundbreaking research initiatives and educational programs aimed at transforming cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Sony Tuteja, PharmD, MS
Principal Investigator
Abramson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported